These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32008229)

  • 1. A Practical Perspective: Application of the Generalized Approach for Adaptive Design.
    Wang J; Li J; Shu Y; Su X
    Ther Innov Regul Sci; 2020 Jan; 54(1):167-170. PubMed ID: 32008229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial.
    Cerqueira FP; Jesus AMC; Cotrim MD
    Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calculating power for the Finkelstein and Schoenfeld test statistic for a composite endpoint with two components.
    Zhou TJ; LaValley MP; Nelson KP; Cabral HJ; Massaro JM
    Stat Med; 2022 Jul; 41(17):3321-3335. PubMed ID: 35486817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size re-estimation in adaptive enrichment design.
    Lin R; Yang Z; Yuan Y; Yin G
    Contemp Clin Trials; 2021 Jan; 100():106216. PubMed ID: 33246098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size re-estimation for survival data in clinical trials with an adaptive design.
    Togo K; Iwasaki M
    Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Information-based sample size re-estimation in group sequential design for longitudinal trials.
    Zhou J; Adewale A; Shentu Y; Liu J; Anderson K
    Stat Med; 2014 Sep; 33(22):3801-14. PubMed ID: 24797715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials.
    Bowden J; Mander A
    Pharm Stat; 2014; 13(3):163-72. PubMed ID: 24692348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and monitoring of clinical trials with an interim analysis and a negative binomial endpoint.
    Quan H; Xu Y; Liu Y; Chen X
    Contemp Clin Trials; 2024 Mar; 138():107467. PubMed ID: 38331382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified Goldilocks Design with strict type I error control in confirmatory clinical trials.
    Zhan T; Zhang H; Hartford A; Mukhopadhyay S
    J Biopharm Stat; 2020 Sep; 30(5):821-833. PubMed ID: 32297825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
    Li Q; Lin J; Lin Y
    Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing a longitudinal clinical trial based on a composite endpoint: Sample size, monitoring, and adaptation.
    Schoenfeld DA; Ramchandani R; Finkelstein DM
    Stat Med; 2022 Oct; 41(24):4745-4755. PubMed ID: 35818331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials.
    Mi MY; Betensky RA
    Clin Trials; 2013 Apr; 10(2):207-15. PubMed ID: 23283576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal adaptive group sequential design with flexible timing of sample size determination.
    Cui L; Zhang L; Yang B
    Contemp Clin Trials; 2017 Dec; 63():8-12. PubMed ID: 28455234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size re-estimation for clinical trials with longitudinal negative binomial counts including time trends.
    Asendorf T; Henderson R; Schmidli H; Friede T
    Stat Med; 2019 Apr; 38(9):1503-1528. PubMed ID: 30575061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extension of a conditional performance score for sample size recalculation rules to the setting of binary endpoints.
    Bokelmann B; Rauch G; Meis J; Kieser M; Herrmann C
    BMC Med Res Methodol; 2024 Jan; 24(1):15. PubMed ID: 38243169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Stat Methods Med Res; 2019 Jun; 28(6):1852-1878. PubMed ID: 29869564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.